Amponsah Seth Kwabena, Tagoe Benjamin, Adams Ismaila, Bugyei Kwasi Agyei
Department of Medical Pharmacology, University of Ghana Medical School, Accra, Ghana.
Fulfillment Operations and Academy, Zipline Ghana, Accra, Ghana.
Front Pharmacol. 2022 Dec 1;13:1063246. doi: 10.3389/fphar.2022.1063246. eCollection 2022.
Due to the fact that coronavirus disease 2019 (COVID-19) is still prevalent, and current reports show that some parts of the world have seen increase in incidence, it is relevant that health professionals and scientists know about recent or novel trends, especially drug treatments. Additionally, the safety profiles of these drug treatments need to be documented and shared with the public. Some studies have demonstrated the clinical benefits of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids in COVID-19 treatment. On the contrary, others have also reported that NSAIDs and corticosteroids may worsen symptoms associated with COVID-19. While some researchers have suggested that corticosteroids may be helpful if used in the early stages of COVID-19, there are still some conflicting findings regarding the use of corticosteroids in certain viral infections. Our review suggests that methylprednisolone, dexamethasone, and ibuprofen have therapeutic potential in reducing mortality due to COVID-19 among hospitalized patients. This review also highlights the fact that the use of NSAIDs is not associated with adverse outcomes of COVID-19. In reality, evidence suggests that NSAIDs do not increase the risk of COVID-19 infections. Also, the literature reviewed suggests that corticosteroid treatment in COVID-19 was linked with a decrease in all-cause mortality and disease progression, without increase in adverse events when compared to no corticosteroid treatment.
由于2019冠状病毒病（COVID-19）仍在流行，且目前的报告显示世界上一些地区的发病率有所上升，卫生专业人员和科学家了解近期或新出现的趋势，尤其是药物治疗，是很有必要的。此外，这些药物治疗的安全性概况需要记录并向公众公布。一些研究已经证明了非甾体抗炎药（NSAIDs）和皮质类固醇在COVID-19治疗中的临床益处。相反，也有其他报告称NSAIDs和皮质类固醇可能会使与COVID-19相关的症状恶化。虽然一些研究人员认为皮质类固醇如果在COVID-19的早期使用可能会有帮助，但在某些病毒感染中使用皮质类固醇仍存在一些相互矛盾的发现。我们的综述表明，甲泼尼龙、地塞米松和布洛芬在降低住院患者因COVID-19导致的死亡率方面具有治疗潜力。本综述还强调了NSAIDs的使用与COVID-19的不良结局无关这一事实。实际上，有证据表明NSAIDs不会增加感染COVID-19的风险。此外，所审查的文献表明，与不使用皮质类固醇治疗相比，COVID-19患者使用皮质类固醇治疗与全因死亡率降低和疾病进展相关，且不良事件没有增加。
